Valuation : Thalia Therapeutics Plc

Market Cap 5.2M 7.04M 6.06M 5.69M 9.71M 666M 9.79M 67.26M 26.19M 340M 26.44M 25.87M 1.1B P/E 2024
-1.69x
P/E 2025 -3.09x
Enterprise Value 4.12M 5.58M 4.8M 4.51M 7.69M 528M 7.76M 53.3M 20.76M 270M 20.96M 20.5M 868M EV / Sales 2024
198,657,512x
EV / Sales 2025 452,941,079x
Free-Float
41.35%
Yield 2024 *
-
Yield 2025 -

Last Transcript : Thalia Therapeutics Plc

1 week-3.85%
Current month-3.85%
1 month-7.41%
3 months-3.85%
6 months+13.64%
Current year+19.05%
1 week 0.6
Extreme 0.6
0.7
1 month 0.6
Extreme 0.6
0.7
Current year 0.4
Extreme 0.4
0.95
1 year 0.4
Extreme 0.4
1
3 years 0.35
Extreme 0.35
1.59
5 years 0.35
Extreme 0.35
9.5
10 years 0.35
Extreme 0.35
35.7
Manager TitleAgeSince
Chief Executive Officer 66 2026-02-23
Chief Operating Officer - -
Chief Tech/Sci/R&D Officer 56 2025-05-26
Director TitleAgeSince
Director/Board Member 48 2020-07-13
Chairman 59 2023-07-31
Director/Board Member 81 2024-09-08
Date Insider Type Main position Quantity % Market Cap. Importance
11/28/24 Free

Founder

6,000,000 1.5198%
11/28/24 Free

Director

3,000,000 0.7599%
11/28/24 Free

Chairman

3,000,000 0.7599%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-3.85%+19.05%-56.90% 7.03M
+0.41%-1.65%+39.85%+95.40% 68.87B
+1.31%+1.65%+50.56%+90.80% 65.29B
+0.04%+4.36%-11.72%+380.39% 27.65B
+2.97%-0.10%+41.86%+14.84% 25.77B
-0.90%-7.65%+2.45%-15.67% 26.08B
+1.01%+1.76%+32.99%-17.16% 20.14B
+3.45%-14.83%+225.22%+389.50% 17.03B
+0.77%-4.55%-0.36%+549.41% 15.03B
+1.03%+7.00%+59.98%+165.51% 14.5B
Average +1.12%-2.58%+45.99%+159.61% 28.04B
Weighted average by Cap. +1.09%-1.63%+43.61%+142.43%

Financials

2024 2025
Net sales 0.01 0.01 0.01 0.01 0.01 0.93 0.01 0.09 0.04 0.48 0.04 0.04 1.53 0.01 0.01 0.01 0.01 0.01 0.93 0.01 0.09 0.04 0.48 0.04 0.04 1.53
Net income -1.06M -1.43M -1.23M -1.16M -1.98M -135M -1.99M -13.69M -5.33M -69.23M -5.38M -5.26M -223M -1.21M -1.63M -1.4M -1.32M -2.25M -154M -2.27M -15.58M -6.07M -78.8M -6.13M -5.99M -254M
Net Debt -626K -847K -729K -684K -1.17M -80.1M -1.18M -8.09M -3.15M -40.94M -3.18M -3.11M -132M -1.08M -1.46M -1.26M -1.18M -2.01M -138M -2.03M -13.96M -5.43M -70.58M -5.49M -5.37M -227M
Logo Thalia Therapeutics Plc
Thalia Therapeutics PLC, formerly N4 Pharma plc, is a biotechnology company developing RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease. The Company is developing proprietary RNA delivery technologies (Nuvec) designed to enable multi-RNA loading, flexible targeting and the potential for oral delivery. Nuvec is based on amorphous silica and has an irregular surface structure that simply and effectively traps and protects RNA as it travels to target cells. The Nuvec delivery system can be functionalized by attaching a wide range of proteins, peptides, antibodies or radionuclides for therapeutic purposes. The Company has a growing pipeline of RNA-based programs across oncology and cardiovascular disease, including Dual-target cardiovascular siRNA program and Proprietary RNA delivery technology. The Company is advancing a novel long-duration, dual-acting siRNA program targeting PCSK9 and lipoprotein.
Employees
3
Date Price Change Volume
26-09-03 GBX 0.6250 0.00% 400,180
26-09-02 GBX 0.6250 -3.85% 434,718
26-09-01 GBX 0.6500 0.00% 2,031,397
26-08-28 GBX 0.6500 0.00% 788,379
26-08-27 GBX 0.6500 0.00% 765,353
  1. Stock Market
  2. Stocks
  3. THAT Stock